Cannabidiol as a Treatment for Mood Disorders : A Systematic Review Le cannabidiol comme traitement des troubles de l’humeur : une revue systématique Jairo Vinicius Pinto, MD, Gayatri Saraf, MD, Christian Frysch, MD, Daniel Vigo, MD, DrPH, Kamyar Keramatian, MD, MSc, FRCPC, Trisha Chakrabarty, MD, Raymond W. Lam, MD, Marcia Kauer-Sant’Anna, MD, PhD, and Lakshmi N. Yatham, MBBS, FRCPC The Canadian Journal of Psychiatry /La Revue Canadienne de Psychiatrie, 2020, Vol. 65, (4), 213-227. Doi : 10.1177/0706743719895195 Abstract Objective : To review the current evidence for efficacy of cannabidiol in the treatment of mood disorders. Methods : We systematically searched PubMed, Embase, Web of Science, PsychInfo, Scielo, [...]
Lire la suiteRole of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders Francisco Navarrete, María Salud García-Gutiérrez, Ani Gasparyan, Amaya Austrich-Olivares and Jorge Manzanares Frontiers in Pharmacology, 2021, 12, Article 696010, 1-24. Doi : 10.3389/fphar.2021.626010 Drug treatments available for the management of substance use disorders (SUD) present multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These facts hamper the clinical outcome and the quality of life of the patients supporting the importance to develop new pharmacological agents. Lately, several reports suggest that cannabidiol (CBD) presents beneficial effects relevant for the management of neurological disorders such as epilepsy, multiple sclerosis, Parkinson’s, or [...]
Lire la suiteCannabidiol EPIDYOLEX 100 mg/ml, solution buvable Première évaluation COMMISSION DE LA TRANSPARENCE AVIS 13 MAI 2020 Haute Autorité de Santé, HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique Avis définitif L’essentiel Avis favorable au remboursement en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut (SLG) ou au syndrome de Dravet (SD), chez les patients de 2 ans et plus. Quel progrès ? Un progrès thérapeutique dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au syndrome de Dravet, chez les patients de 2 ans et plus. Quelle place dans la stratégie thérapeutique ? Crises d’épilepsie [...]
Lire la suitePharmacologie du Cannabidiol : Points de vigilance, conséquences et risques chez l’homme Note rédigée par l’Association Française des centres d’Addictovigilance : Pr Joëlle MICALLEF, Dr Anne BATISSE, Dr Bruno REVOL, décembre 2021 Contexte Le Cannabidiol (CBD) est l’un des principaux phytocannabinoïdes présent dans Cannabis sativa, avec le THC. A ce jour, un seul produit contenant uniquement du CBD (nom de ce médicament Epidyolex®) est disponible sur le marché français, son Autorisation de Mise sur le Marché (AMM) lui conférant une indication médicale en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au syndrome de Dravet, chez les [...]
Lire la suiteCANNABIDIOL (CBD) : Critical Review Report, WHO, 2018 Expert Committee on Drug Dependence Fortieth Meeting Geneva, 4-7 June 2018 Contents Acknowledgements .................................................................................................................. 4 Summary................................................................................................................................... 5 1. Substance identification ........................................................................................................ 6 A. International Nonproprietary Name (INN) ............................................................................ 6 B. Chemical Abstract Service (CAS) Registry Number .............................................................. 6 C. Other Chemical Names .......................................................................................................... 6 D. Trade Names .......................................................................................................................... 6 E. Street Names........................................................................................................................... 6 F. Physical Appearance.............................................................................................................. 6 G. WHO Review History ............................................................................................................. 6 2. Chemistry ............................................................................................................................... 6 A. Chemical Name ...................................................................................................................... 6 B. Chemical Structure................................................................................................................. 7 C. Stereoisomers ......................................................................................................................... 7 D. Methods and Ease of Illicit Manufacturing............................................................................ 7 E. Chemical Properties............................................................................................................... 9 F. Identification and Analysis ..................................................................................................... 9 3. Ease of Convertibility Into Controlled Substances ............................................................ 10 4. General Pharmacology........................................................................................................ 11 A. Routes of administration and [...]
Lire la suiteReal life Experience of Medical Cannabis Treatment in Autism : Analysis of Safety and Efficacy Lihi Bar-Lev Schleider, Raphael Mechoulam, Naama Saban, Gal Meiri & Victor Novack Scientific Reports, Nature.com, 2019, 9, 200, 1-7 Doi : 10.1038/s41598-018-37570-y There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. Recently anecdotal evidence of possible therapeutic effects of cannabis products has emerged. The aim of this study is to characterize the epidemiology of ASD patients receiving medical cannabis treatment and to describe its safety and efficacy. We analysed the data prospectively collected as part of the treatment program of [...]
Lire la suiteCurrent state of evidence of cannabis utilization for treatment of autism spectrum disorders Rumi Agarwal, Shanna L. Burke and Marlaina Maddux BMC Psychiatry, 2019, 19, 328 Doi : 10.1186/s12888-019-2259-4 Abstract The core symptoms and co-morbidities associated with autism spectrum disorders (ASD) affect daily living and quality of life. Existing pharmacological interventions are only able to attenuate some related symptoms but are unable to address the underlying etiologies associated with ASD. Anecdotal evidence, which claims benefit from the use of cannabis to treat symptoms among this population, has been gaining popularity as families seek solutions. This paper analyzed recent peer-reviewed literature to identify the current state of [...]
Lire la suiteThe effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD) Charlotte M. Pretzsch, Bogdan Voinescu, Maria A. Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Steven Williams, Declan GM Murphy, Eileen Daly and Gráinne M. McAlonan Journal of Psychopharmacology, 2019, Vol. 33, (9), 1141–1148 Doi : 10.1177/0269881119858306 Abstract Background : The potential benefits of cannabis and its major non-intoxicating component cannabidiol (CBD) are attracting attention, including as a potential treatment in neurodevelopmental disorders such as autism spectrum disorder (ASD). However, the neural action of CBD, and its relevance to ASD, remains [...]
Lire la suiteEffects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, 2019, volume 10, Article 1146, 1-9. doi : 10.3389/fneur.2019.01145 Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]
Lire la suiteOral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities Dana Barchel, Orit Stolar2, Tal De-Haan, Tomer Ziv-Baran, Naama Saban, Danny Or Fuchs, Gideon Koren and Matitiahu Berkovitch Frontiers in Pharmacology, 2019, volume 9, article 1521, 1-5 Doi : 10.3389/fphar.2018.01521 Objective : Children with autism spectrum disorder (ASD) commonly exhibit comorbid symptoms such as aggression, hyperactivity and anxiety. Several studies are being conducted worldwide on cannabidiol use in ASD; however, these studies are still ongoing, and data on the effects of its use is very limited. In this study we aimed to report the experience of parents who administer, [...]
Lire la suite